Ibogaine for Alcohol Dependency

The live analytics dashboard below draws its values from MindScape Retreat's clinical records system and renders only when the alcohol dependency cohort holds real assessment data, tracking clinical trajectories from admission through 90-day follow-up. Because alcohol withdrawal involves distinct neurological risks that opioid withdrawal does not, including tonic-clonic seizure potential, autonomic dysregulation, and delirium tremens, the assessment instruments used in this cohort differ fundamentally from those applied in opioid dependency studies. The primary clinical instruments are the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised) and the AUDIT (Alcohol Use Disorders Identification Test), which together capture both acute withdrawal severity and the pattern of harmful alcohol use that sustains dependency beyond the initial cessation period.

Unlike opioid-specific instruments such as COWS or SOWS, which measure predominantly adrenergic and autonomic withdrawal signs, the CIWA-Ar assesses ten neurological domains (including perceptual disturbances and orientation) that reflect the GABAergic and glutamatergic mechanisms uniquely disrupted by chronic alcohol exposure. The dashboard tracks how these alcohol-specific trajectories respond to ibogaine's multi-receptor mechanism across the full cohort.

What the trajectories are built to test is ibogaine's GABAergic and glutamatergic mechanism of action in alcohol dependency. The first 72 hours after ibogaine administration is the window where NMDA receptor antagonism would blunt the glutamate rebound that drives the most dangerous phase of alcohol withdrawal, so CIWA-Ar is scored daily across it. Craving should move on a parallel but slightly delayed arc, because the progressive normalization of dopaminergic reward circuitry through BDNF and GDNF upregulation runs on a slower clock than glutamate stabilization.

One clinically important feature of this population is alcohol kindling: the progressive intensification of withdrawal syndromes across successive detox episodes, driven by glutamate receptor sensitization and well documented in the alcohol withdrawal literature. It is the reason a fifth detox is harder than a first, and the reason prior failed attempts are recorded at intake rather than treated as background. Ibogaine's NMDA modulation is aimed at interrupting that sensitization cycle rather than suppressing a single withdrawal episode, which is the mechanistic claim the 90-day timepoint exists to test.

Two instruments carry the clinical weight in alcohol dependency, and both are worth understanding before any number is read. The CIWA-Ar is a 10-domain observer-rated scale covering nausea and vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache or fullness in the head, and clouding of sensorium. It is scored from 0 to 67, with scores below 8 indicating absent or minimal withdrawal, 8 to 15 indicating mild withdrawal, 16 to 20 indicating moderate withdrawal, and scores above 20 indicating severe withdrawal with significant risk of tonic-clonic seizure and delirium tremens. The AUDIT, developed by the World Health Organization, measures the full spectrum of harmful alcohol use across 10 items including consumption frequency, binge drinking, dependence symptoms, and social harm, scored from 0 to 40.

Guests who arrive in the severe withdrawal range are the reason this protocol runs inpatient with continuous telemetry: standard clinical guidance recommends inpatient monitoring above a CIWA-Ar of 20 because of seizure risk. On the AUDIT, a score above 20 is what the WHO defines as probable alcohol dependence requiring specialized intervention. Both instruments are scored at admission, daily through the inpatient phase, and again at 30, 60, and 90 days, so the trajectory is recorded rather than recalled.

The CIWA-Ar and the AUDIT capture the clinical and diagnostic dimensions of alcohol dependency (the acute withdrawal syndrome and the pattern of harmful use), but neither directly measures the subjective craving that drives relapse in the weeks and months following detox. That is why the protocol also scores a Visual Analog Scale for Craving (VAS Craving, 0 to 100) alongside weekly alcohol consumption units, together the two most behaviorally predictive indicators of long-term abstinence. Where the CIWA-Ar measures what the body does when alcohol is removed, the VAS Craving measures what the mind continues to demand, and it is this craving dimension that conventional detox most consistently fails to resolve.

Taken together, these four measures are designed to catch the two failure modes of conventional alcohol treatment at once: a detox that resolves the acute withdrawal syndrome but leaves the craving architecture intact, and a craving intervention that never safely gets the patient through withdrawal. Ibogaine's NMDA antagonism is aimed at the GABAergic and glutamatergic instability behind the first; its BDNF and GDNF upregulation at the mesolimbic dopamine pathways through which alcohol maintains its motivational grip behind the second. Detox without craving resolution invariably leads to relapse once the acute phase passes, and that is the single most common reason conventional treatment fails.

What we will not do is publish a number before it is real. Structured outcome collection in this program began in July 2026, and no alcohol cohort has yet reached the publication threshold of 20 people with paired baseline and follow-up data. When one does, the aggregates go up at mindscaperetreat.com/outcomes with the instrument, the timepoint, and the cohort size stated. The methodology that will produce them is detailed in the section below.